Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Capital Expenditures: 2016-2024

Historic Capital Expenditures for Solid Biosciences (SLDB) over the last 9 years, with Dec 2024 value amounting to $654,000.

  • Solid Biosciences' Capital Expenditures rose 126.67% to $204,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $654,000, marking a year-over-year decrease of 56.83%. This contributed to the annual value of $654,000 for FY2024, which is 56.83% down from last year.
  • Latest data reveals that Solid Biosciences reported Capital Expenditures of $654,000 as of FY2024, which was down 56.83% from $1.5 million recorded in FY2023.
  • In the past 5 years, Solid Biosciences' Capital Expenditures registered a high of $3.0 million during FY2022, and its lowest value of $654,000 during FY2024.
  • In the last 3 years, Solid Biosciences' Capital Expenditures had a median value of $1.5 million in 2023 and averaged $1.7 million.
  • As far as peak fluctuations go, Solid Biosciences' Capital Expenditures plummeted by 79.51% in 2020, and later surged by 135.36% in 2022.
  • Solid Biosciences' Capital Expenditures (Yearly) stood at $899,000 in 2020, then spiked by 42.49% to $1.3 million in 2021, then surged by 135.36% to $3.0 million in 2022, then slumped by 49.75% to $1.5 million in 2023, then crashed by 56.83% to $654,000 in 2024.